Inozyme Pharma, Inc.
NASDAQ:INZY
5.15 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.294 | 1.177 | 1.052 | 0.217 | 0.083 | 0.026 |
| Gross Profit
| -1.294 | -1.177 | -1.052 | -0.217 | -0.083 | -0.026 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 54.847 | 47.849 | 37.72 | 46.493 | 16.22 | 8.099 |
| General & Administrative Expenses
| 20.798 | 20.826 | 18.926 | 10.548 | 4.586 | 3.494 |
| Selling & Marketing Expenses
| -0.494 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 20.798 | 20.826 | 18.926 | 10.548 | 4.586 | 3.494 |
| Other Expenses
| 0 | -0.319 | -0.189 | 0.247 | -0.024 | 4.345 |
| Operating Expenses
| 75.645 | 68.675 | 56.646 | 57.041 | 20.806 | 11.593 |
| Operating Income
| -75.645 | -68.675 | -56.646 | -57.041 | -20.806 | -11.593 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.476 | 1.614 | 0.022 | 0.617 | 1.082 | 4.345 |
| Income Before Tax
| -71.169 | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.614 | -0.211 | -0.587 | -1.106 | 4.629 |
| Net Income
| -71.169 | -65.447 | -56.413 | -55.837 | -18.618 | -6.964 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted
| -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EBITDA
| -74.812 | -68.675 | -55.972 | -57.041 | -20.723 | -11.567 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |